Data collected from awardees by report type.

Report Type	Report Elements
Monthly Report	Total doses of hepatitis B (HepB) vaccine ordered to date Number of HepB vaccine doses ordered in the past month Number of doses administered in the past month Project expenditures Progress toward achieving project objectives as stated in the proposal application Accomplishments and significant events Challenges encountered, their impact on project objectives and timelines, and proposed solutions Planned activities for the next month Whether the project was proceeding on schedule as per the project proposal
Quarterly Narrative Update	Successes and challenges of vaccination of individuals at increased risk for HBV infection Successes and challenges of implementation of strategies shown to improve vaccine uptake, including reminder/recall processes, standing orders, and immunization information system (IIS) use Pilot HepB dose wastagea Reasons for wastageb Anticipated number of unused doses by the pilot end date Sustainability of the HepB vaccination activities after the pilot ended Any substantial changes in the epidemiology of HepB cases in the jurisdiction
Quarterly Quantitative Update	Number of patient visits to the sites Number of patients offered HepB vaccine Number of HepB doses ordered and administered by facility type and by demographics Number of doses completed in the 3-dose HepB vaccine series Hepatitis B risk factors, which included the number of doses administered by risk factors for sites without universal HepB vaccination recommendation Information on hepatitis B surface antigen and antibody testing (if done)c
Final Report	Executive summary Information on the implementation of HepB vaccination in universal and non-universal settingsd Evaluation of the interventions Summary of outcome measures Description of challenges, barriers, successes, and lessons learned from efforts to vaccinate individuals at increased for HBV infection Sustainability of HepB vaccination activities Data collection instruments and other materials produced for the pilot Measures of success of the project by setting typee Number of doses ordered and administeredf Number of patients seen at the setting Percentage of clients offered HepB vaccine First dose acceptance rates Proportion of first dose recipients receiving second and third doses Characteristics of vaccine recipientsg

^aInformation about dose wastage was not originally incorporated into the report template, but was included in later revisions.

^bE.g., doses that were not used prior to reaching their expiration dates or vaccine that was unable to be used because of temperature storage errors or mishaps.

^cAlthough three awardees provided some information on testing, each reported information differently and the completeness of reporting of testing could not be determined. Thus, information regarding testing was not included in the final summary report for the HepB Pilot project.

^dI.e., practices regarding communication and training with sites, vaccination strategies to identify and offer vaccination to persons at risk for HepB, and IIS use to capture doses administered and dose-series completion. Universal settings include those settings where a high proportion of persons who see care have risk factors for HBV infection, such as sexually transmitted disease (STD) clinics, HIV clinics, correctional facilities, and drug treatment centers. Non-universal settings would include general medical care clinics such as the health department, community health centers, or primary care clinics.

^eE.g., corrections, STD clinics, other health department clinics, drug treatment centers.

^fAwardees that did not utilize all of their allotted HepB vaccine by the time the project ended in September 2015 (including the 1-year no-cost extension) were asked to report monthly regarding the number of doses administered, number of doses unused, and number of doses that had expired or been unused due to other reasons such as interruptions in maintaining recommended storage conditions.

^gSuch as age, race/ethnicity, sex, specific risk factor(s) for HBV infection, to assess if awardees were accessing persons at greatest risk of HBV infection in their jurisdictions.